Compare CRON & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRON | GERN |
|---|---|---|
| Founded | N/A | 1990 |
| Country | Canada | United States |
| Employees | N/A | 258 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 985.8M | 808.3M |
| IPO Year | 2015 | N/A |
| Metric | CRON | GERN |
|---|---|---|
| Price | $2.73 | $1.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 1.6M | ★ 14.2M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $146,587,000.00 | N/A |
| Revenue This Year | $26.34 | $26.91 |
| Revenue Next Year | $15.53 | $43.75 |
| P/E Ratio | $68.38 | ★ N/A |
| Revenue Growth | ★ 24.63 | N/A |
| 52 Week Low | $1.84 | $1.04 |
| 52 Week High | $3.43 | $2.01 |
| Indicator | CRON | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 35.09 |
| Support Level | $2.47 | $1.24 |
| Resistance Level | $2.72 | $1.29 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 39.23 | 14.29 |
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.